JP2024506708A5 - - Google Patents

Info

Publication number
JP2024506708A5
JP2024506708A5 JP2023549573A JP2023549573A JP2024506708A5 JP 2024506708 A5 JP2024506708 A5 JP 2024506708A5 JP 2023549573 A JP2023549573 A JP 2023549573A JP 2023549573 A JP2023549573 A JP 2023549573A JP 2024506708 A5 JP2024506708 A5 JP 2024506708A5
Authority
JP
Japan
Prior art keywords
antibody
composition according
chain variable
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506708A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/076554 external-priority patent/WO2022174775A1/en
Publication of JP2024506708A publication Critical patent/JP2024506708A/ja
Publication of JP2024506708A5 publication Critical patent/JP2024506708A5/ja
Pending legal-status Critical Current

Links

JP2023549573A 2021-02-18 2022-02-17 特定の乳癌の治療におけるher2を標的とする抗体薬物複合体の使用 Pending JP2024506708A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110189905 2021-02-18
CN202110189905.8 2021-02-18
CN202110506596 2021-05-10
CN202110506596.2 2021-05-10
PCT/CN2022/076554 WO2022174775A1 (en) 2021-02-18 2022-02-17 Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer

Publications (2)

Publication Number Publication Date
JP2024506708A JP2024506708A (ja) 2024-02-14
JP2024506708A5 true JP2024506708A5 (cg-RX-API-DMAC7.html) 2025-02-27

Family

ID=82931194

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549573A Pending JP2024506708A (ja) 2021-02-18 2022-02-17 特定の乳癌の治療におけるher2を標的とする抗体薬物複合体の使用

Country Status (11)

Country Link
US (1) US20240148894A1 (cg-RX-API-DMAC7.html)
EP (1) EP4294455A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024506708A (cg-RX-API-DMAC7.html)
KR (1) KR20230146526A (cg-RX-API-DMAC7.html)
CN (1) CN117460538A (cg-RX-API-DMAC7.html)
AU (1) AU2022222937A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206798A1 (cg-RX-API-DMAC7.html)
IL (1) IL305095A (cg-RX-API-DMAC7.html)
MX (1) MX2023009376A (cg-RX-API-DMAC7.html)
TW (1) TW202241523A (cg-RX-API-DMAC7.html)
WO (1) WO2022174775A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111655295B (zh) 2018-08-29 2024-05-28 荣昌生物制药(烟台)股份有限公司 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途
EP4676543A1 (en) * 2023-03-10 2026-01-14 Seagen Inc. Methods of treating cancer using anti-her2 antibody-drug conjugates and her2 kinase inhibitors
WO2025054918A1 (en) * 2023-09-14 2025-03-20 Remegen Co., Ltd. Methods of treating cancer using anti-her2 antibody-drug conjugates and anti-pd-1 antibodies
WO2025054916A1 (en) * 2023-09-14 2025-03-20 Remegen Co., Ltd. Methods of treating cervical cancer using anti-her2 antibody-drug conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3480215T (pt) * 2013-11-19 2021-07-05 Remegen Ltd Anticorpo anti-her2 e seu conjugado
US10689458B2 (en) * 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
SG11202104269PA (en) * 2019-03-26 2021-05-28 Remegen Co Ltd Anti-her2 antibody drug conjugate pharmaceutical preparation

Similar Documents

Publication Publication Date Title
US20260139074A1 (en) Combination of antibody-drug conjugate and tubulin inhibitor
CN106459200B (zh) 抗-egfr抗体及抗体药物偶联物
KR102115217B1 (ko) 항-folr1 면역접합체 투여 레지멘
JP2020509027A5 (cg-RX-API-DMAC7.html)
JP2012522513A5 (cg-RX-API-DMAC7.html)
WO2023036137A1 (en) Process for preparing highly homogenous antibody-drug conjugates for engineered antibodies
TW200404005A (en) Calicheamicin derivative-carrier conjugates
JP2015523961A5 (cg-RX-API-DMAC7.html)
CA3093731A1 (en) Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
TW202216212A (zh) 抗體-藥物結合物之製造方法
RU2019141270A (ru) Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител
WO2022174775A1 (en) Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer
TW202330040A (zh) 抗her2抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途
US20260115306A1 (en) Combination of anti-cdh6 antibody-drug conjugate and vegf inhibitor
JP2025508380A5 (cg-RX-API-DMAC7.html)
JP2023546293A5 (cg-RX-API-DMAC7.html)
RU2023123868A (ru) Применение конъюгата антитело-лекарственное средство, нацеленного на her2, в лечении специфичного рака молочной железы
TW202033217A (zh) 一種c-Met ADC在製備治療c-Met激酶抑制劑耐藥的疾病的藥物中的用途
JP2024540536A5 (cg-RX-API-DMAC7.html)
RU2023134007A (ru) Применение конъюгата антитело-лекарственное средство в комбинации с ингибитором иммунных контрольных точек в лечении уротелиального рака
RU2023134008A (ru) Применение конъюгата, нацеленное на her2 антитело - лекарственное средство, в лечении рака молочной железы с низкой экспрессией her2
CN114845738A (zh) 使用位点特异性her2抗体-药物缀合物的治疗
TW202615102A (zh) 抗體藥物偶聯物用於治療癌症的方法
RU2020136692A (ru) Конъюгаты антител с лекарственными веществами и их применение для лечения раковых заболеваний
RU2023128710A (ru) Антитела против c-met и коньюгаты антитела с лекарственным средством